NYBR1 Expression in Breast and Gynecologic Tract Carcinomas.
Anna H Woodard, Jing Yu, David J Dabbs, Anca V Florea, Sushil Beriwal, Rohit Bhargava. Magee-Womens Hospital of UPMC, Pittsburgh, PA
Background: The distinction of breast carcinomas from CK7+/ER+/CK20 negative gynecologic tumors is often difficult and other immunohistochemical markers, such as mammaglobin, may be positive in both. GCDFP-15 has low sensitivity to be an effective breast marker. Vimentin stains endometrioid endometrial carcinomas, but in one third of cases may be negative or focally expressed. NYBR1 is a mammary differentiation antigen that may be helpful in these difficult cases.
Design: Tissue microarrays containing 185 primary breast carcinomas and 142 gynecologic carcinomas were stained with NYBR1 mouse monoclonal antibody (NY-BR-1#2). All tumors were semi-quantitatively scored using the H-score method where the score ranges from 0 (negative) to 300 (diffuse strong reactivity).
Results: Among primary breast carcinomas, the overall sensitivity of NYBR1 was 60% (H-score >10). Sensitivity was slightly higher for ER+ tumors: 70% (104/148).
|Breast tumor group||H-score 0||H-score 1-10||H-score 11-50||H-score 51-150||H-score >150||Total|
|Site and tumor type||NYBR1 negative||NYBR1 positive||Total|
|Ovarian clear cell||34||0||34|